LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
NCT00525148
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
129
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG:
BIBW 2992
Sponsor
Boehringer Ingelheim